

Omar Abdel-Wahab

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4266623/publications.pdf>

Version: 2024-02-01

267
papers

36,579
citations

3525

90
h-index

3402

183
g-index

291
all docs

291
docs citations

291
times ranked

35796
citing authors

#	ARTICLE	IF	CITATIONS
1	Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. <i>Cancer Cell</i> , 2010, 18, 553-567.	7.7	2,328
2	The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α -Ketoglutarate to 2-Hydroxyglutarate. <i>Cancer Cell</i> , 2010, 17, 225-234.	7.7	1,754
3	IDH mutation impairs histone demethylation and results in a block to cell differentiation. <i>Nature</i> , 2012, 483, 474-478.	13.7	1,693
4	Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2012, 366, 1079-1089.	13.9	1,688
5	Clinical Effect of Point Mutations in Myelodysplastic Syndromes. <i>New England Journal of Medicine</i> , 2011, 364, 2496-2506.	13.9	1,444
6	Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation. <i>Cancer Cell</i> , 2011, 20, 11-24.	7.7	1,105
7	Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. <i>Blood</i> , 2016, 127, 2672-2681.	0.6	1,040
8	EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation. <i>Cancer Cell</i> , 2013, 23, 677-692.	7.7	706
9	Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. <i>Nature Genetics</i> , 2012, 44, 1179-1181.	9.4	692
10	Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. <i>Blood</i> , 2009, 114, 144-147.	0.6	661
11	The role of mutations in epigenetic regulators in myeloid malignancies. <i>Nature Reviews Cancer</i> , 2012, 12, 599-612.	12.8	614
12	RNA splicing factors as oncoproteins and tumour suppressors. <i>Nature Reviews Cancer</i> , 2016, 16, 413-430.	12.8	549
13	Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression. <i>Cell</i> , 2017, 170, 1079-1095.e20.	13.5	522
14	ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression. <i>Cancer Cell</i> , 2012, 22, 180-193.	7.7	504
15	Therapeutic targeting of splicing in cancer. <i>Nature Medicine</i> , 2016, 22, 976-986.	15.2	484
16	Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. <i>Blood</i> , 2014, 124, 483-492.	0.6	462
17	SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. <i>Cancer Cell</i> , 2015, 27, 617-630.	7.7	449
18	BET inhibitor resistance emerges from leukaemia stem cells. <i>Nature</i> , 2015, 525, 538-542.	13.7	441

#	ARTICLE	IF	CITATIONS
19	Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2012, 30, 3376-3382.	0.8	419
20	BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. <i>Cancer Cell</i> , 2015, 28, 370-383.	7.7	392
21	H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. <i>Nature Medicine</i> , 2018, 24, 497-504.	15.2	391
22	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. <i>Cancer Discovery</i> , 2016, 6, 154-165.	7.7	372
23	Loss of the Tumor Suppressor BAP1 Causes Myeloid Transformation. <i>Science</i> , 2012, 337, 1541-1546.	6.0	355
24	A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. <i>Nature</i> , 2011, 473, 230-233.	13.7	351
25	Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. <i>Blood</i> , 2014, 123, e123-e133.	0.6	337
26	Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. <i>Nature</i> , 2012, 489, 155-159.	13.7	320
27	Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. <i>Nature Medicine</i> , 2016, 22, 672-678.	15.2	301
28	Loss of BAP1 function leads to EZH2-dependent transformation. <i>Nature Medicine</i> , 2015, 21, 1344-1349.	15.2	297
29	Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 1733-1747.	13.9	281
30	Vemurafenib for BRAF V600E Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis. <i>JAMA Oncology</i> , 2018, 4, 384.	3.4	280
31	Genetic Analysis of Transforming Events That Convert Chronic Myeloproliferative Neoplasms to Leukemias. <i>Cancer Research</i> , 2010, 70, 447-452.	0.4	279
32	Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. <i>Journal of Experimental Medicine</i> , 2013, 210, 2641-2659.	4.2	278
33	The Notch/Hes1 Pathway Sustains NF- κ B Activation through CYLD Repression in T Cell Leukemia. <i>Cancer Cell</i> , 2010, 18, 268-281.	7.7	261
34	JAK-STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response. <i>Cancer Discovery</i> , 2015, 5, 316-331.	7.7	252
35	Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. <i>Blood</i> , 2016, 127, 3004-3014.	0.6	244
36	Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E5401-10.	3.3	238

#	ARTICLE	IF	CITATIONS
37	Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2019, 35, 369-384.e7.	7.7	238
38	DNA Hydroxymethylation Profiling Reveals that WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia. <i>Cell Reports</i> , 2014, 9, 1841-1855.	2.9	237
39	JAK2V617F-Mediated Phosphorylation of PRMT5 Downregulates Its Methyltransferase Activity and Promotes Myeloproliferation. <i>Cancer Cell</i> , 2011, 19, 283-294.	7.7	225
40	Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment. <i>New England Journal of Medicine</i> , 2012, 367, 2316-2321.	13.9	222
41	Efficacy of MEK inhibition in patients with histiocytic neoplasms. <i>Nature</i> , 2019, 567, 521-524.	13.7	222
42	Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. <i>Blood</i> , 2013, 121, 3563-3572.	0.6	218
43	TET Family Proteins and Their Role in Stem Cell Differentiation and Transformation. <i>Cell Stem Cell</i> , 2011, 9, 193-204.	5.2	209
44	Somatic mutations and cell identity linked by Genotyping of Transcriptomes. <i>Nature</i> , 2019, 571, 355-360.	13.7	206
45	The Augmented R-Loop Is a Unifying Mechanism for Myelodysplastic Syndromes Induced by High-Risk Splicing Factor Mutations. <i>Molecular Cell</i> , 2018, 69, 412-425.e6.	4.5	203
46	Macrophages support pathological erythropoiesis in polycythemia vera and β^2 -thalassemia. <i>Nature Medicine</i> , 2013, 19, 437-445.	15.2	202
47	EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. <i>Cancer Cell</i> , 2016, 30, 197-213.	7.7	200
48	Clinical and Pathologic Impact of Select Chromatin-modulating Tumor Suppressors in Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2013, 63, 848-854.	0.9	198
49	Comprehensive mutational profiling of core binding factor acute myeloid leukemia. <i>Blood</i> , 2016, 127, 2451-2459.	0.6	198
50	Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. <i>Blood</i> , 2014, 124, 3016-3019.	0.6	197
51	DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. <i>Nature Medicine</i> , 2016, 22, 1488-1495.	15.2	195
52	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. <i>Blood</i> , 2017, 129, 553-560.	0.6	193
53	Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. <i>Blood</i> , 2012, 119, 4480-4485.	0.6	189
54	Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α -2a. <i>Blood</i> , 2013, 122, 893-901.	0.6	184

#	ARTICLE	IF	CITATIONS
55	Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation. <i>Cancer Cell</i> , 2019, 36, 194-209.e9.	7.7	184
56	Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. <i>Blood</i> , 2013, 121, 4917-4924.	0.6	175
57	Widespread intronic polyadenylation inactivates tumour suppressor genes in leukaemia. <i>Nature</i> , 2018, 561, 127-131.	13.7	172
58	Diagnosis and classification of hematologic malignancies on the basis of genetics. <i>Blood</i> , 2017, 130, 410-423.	0.6	163
59	The clinical spectrum of Erdheim-Chester disease: an observational cohort study. <i>Blood Advances</i> , 2017, 1, 357-366.	2.5	163
60	Spliceosomal disruption of the non-canonical BAF complex in cancer. <i>Nature</i> , 2019, 574, 432-436.	13.7	163
61	Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations. <i>Cancer Cell</i> , 2018, 34, 225-241.e8.	7.7	162
62	HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. <i>Journal of Clinical Investigation</i> , 2010, 120, 3578-3593.	3.9	162
63	Histiocytoses: emerging neoplasia behind inflammation. <i>Lancet Oncology</i> , The, 2017, 18, e113-e125.	5.1	154
64	DNA methylation disruption reshapes the hematopoietic differentiation landscape. <i>Nature Genetics</i> , 2020, 52, 378-387.	9.4	154
65	Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. <i>Journal of Clinical Investigation</i> , 2015, 125, 1857-1872.	3.9	151
66	Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. <i>Nature</i> , 2019, 574, 273-277.	13.7	149
67	Notch pathway activation targets AML-initiating cell homeostasis and differentiation. <i>Journal of Experimental Medicine</i> , 2013, 210, 301-319.	4.2	148
68	Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. <i>Journal of Clinical Investigation</i> , 2020, 130, 981-997.	3.9	146
69	A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. <i>Nature</i> , 2017, 549, 389-393.	13.7	144
70	The Potential for Isocitrate Dehydrogenase Mutations to Produce 2-Hydroxyglutarate Depends on Allele Specificity and Subcellular Compartmentalization. <i>Journal of Biological Chemistry</i> , 2013, 288, 3804-3815.	1.6	141
71	Myelodysplastic syndromes are induced by histone methylation- and altering ASXL1 mutations. <i>Journal of Clinical Investigation</i> , 2013, 123, 4627-4640.	3.9	140
72	GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. <i>Blood</i> , 2013, 121, 5068-5077.	0.6	137

#	ARTICLE	IF	CITATIONS
73	Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. <i>Blood</i> , 2017, 130, 167-175.	0.6	136
74	Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. <i>Cell</i> , 2021, 184, 4032-4047.e31.	13.5	131
75	Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development. <i>Cancer Cell</i> , 2016, 30, 92-107.	7.7	130
76	Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. <i>Nature Medicine</i> , 2015, 21, 1473-1480.	15.2	128
77	Cross-talk between PRMT1-mediated methylation and ubiquitylation on RBM15 controls RNA splicing. <i>ELife</i> , 2015, 4, .	2.8	125
78	Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. <i>Molecular Cell</i> , 2015, 59, 345-358.	4.5	125
79	Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. <i>Nature Medicine</i> , 2019, 25, 1839-1842.	15.2	122
80	A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 17604-17609.	3.3	119
81	Prospective Blinded Study of <i>BRAF</i> V600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders. <i>Cancer Discovery</i> , 2015, 5, 64-71.	7.7	115
82	Expression of mutant <i>Asxl1</i> perturbs hematopoiesis and promotes susceptibility to leukemic transformation. <i>Journal of Experimental Medicine</i> , 2018, 215, 1729-1747.	4.2	113
83	Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. <i>Blood</i> , 2017, 130, 397-407.	0.6	112
84	Regulation of c-Myc Ubiquitination Controls Chronic Myelogenous Leukemia Initiation and Progression. <i>Cancer Cell</i> , 2013, 23, 362-375.	7.7	111
85	Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. <i>Nature Biotechnology</i> , 2022, 40, 499-506.	9.4	110
86	Altered RNA Processing in Cancer Pathogenesis and Therapy. <i>Cancer Discovery</i> , 2019, 9, 1493-1510.	7.7	106
87	Frequent <i>ASXL2</i> mutations in acute myeloid leukemia patients with t(8;21)/ <i>RUNX1-RUNX1T1</i> chromosomal translocations. <i>Blood</i> , 2014, 124, 1445-1449.	0.6	105
88	Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. <i>Blood</i> , 2016, 127, 1551-1558.	0.6	105
89	Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod,) Tj ETQq1 1 0.784314 rgBT /Overlock 104	0.6	104
90	Hematopoietic Stem Cell Origin of <i>BRAF</i> V600E Mutations in Hairy Cell Leukemia. <i>Science Translational Medicine</i> , 2014, 6, 238ra71.	5.8	102

#	ARTICLE	IF	CITATIONS
91	The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort. <i>Modern Pathology</i> , 2018, 31, 581-597.	2.9	102
92	KMT2C mediates the estrogen dependence of breast cancer through regulation of ER α enhancer function. <i>Oncogene</i> , 2018, 37, 4692-4710.	2.6	102
93	Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. <i>Blood Advances</i> , 2021, 5, 1552-1564.	2.5	102
94	Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. <i>Cancer Cell</i> , 2020, 38, 198-211.e8.	7.7	99
95	Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. <i>Blood</i> , 2017, 130, 176-180.	0.6	98
96	High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. <i>Blood</i> , 2017, 130, 1007-1013.	0.6	98
97	Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. <i>Cancer Discovery</i> , 2018, 8, 648-661.	7.7	97
98	Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis. <i>Genes and Development</i> , 2016, 30, 989-1001.	2.7	95
99	CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. <i>Blood</i> , 2012, 120, 2297-2306.	0.6	92
100	Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors. <i>New England Journal of Medicine</i> , 2022, 386, 735-743.	13.9	87
101	Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen. <i>Blood</i> , 2011, 118, 5330-5339.	0.6	86
102	Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations. <i>Blood</i> , 2017, 130, 1644-1648.	0.6	82
103	The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics. <i>Leukemia</i> , 2013, 27, 10-15.	3.3	78
104	Emerging concepts of epigenetic dysregulation in hematological malignancies. <i>Nature Immunology</i> , 2016, 17, 1016-1024.	7.0	77
105	Mutations in Epigenetic Modifiers in Myeloid Malignancies and the Prospect of Novel Epigenetic-Targeted Therapy. <i>Advances in Hematology</i> , 2012, 2012, 1-12.	0.6	73
106	Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies. <i>Cancer Discovery</i> , 2014, 4, 538-545.	7.7	73
107	Aberrant RNA Splicing in Cancer. <i>Annual Review of Cancer Biology</i> , 2019, 3, 167-185.	2.3	73
108	Mutations in the RNA Splicing Factor SF3B1 Promote Tumorigenesis through MYC Stabilization. <i>Cancer Discovery</i> , 2020, 10, 806-821.	7.7	73

#	ARTICLE	IF	CITATIONS
109	Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. <i>Blood</i> , 2010, 115, 2919-2927.	0.6	72
110	Metabolism and the leukemic stem cell. <i>Journal of Experimental Medicine</i> , 2010, 207, 677-680.	4.2	70
111	D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. <i>Genes and Development</i> , 2014, 28, 479-490.	2.7	70
112	Dysregulation and therapeutic targeting of RNA splicing in cancer. <i>Nature Cancer</i> , 2022, 3, 536-546.	5.7	65
113	Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL. <i>Nature Communications</i> , 2019, 10, 1874.	5.8	63
114	Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition. <i>Nature Genetics</i> , 2021, 53, 707-718.	9.4	61
115	Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis. <i>Cancer Discovery</i> , 2019, 9, 1452-1467.	7.7	60
116	Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. <i>Oncotarget</i> , 2016, 7, 85430-85436.	0.8	60
117	Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene <i>U2af1</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E10437-E10446.	3.3	59
118	Molecular classification improves risk assessment in adult <i>BCR-ABL1</i> negative B-ALL. <i>Blood</i> , 2021, 138, 948-958.	0.6	59
119	Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition. <i>Molecular Cell</i> , 2021, 81, 2183-2200.e13.	4.5	59
120	Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. <i>Haematologica</i> , 2013, 98, 591-596.	1.7	58
121	SnapShot: Splicing Alterations in Cancer. <i>Cell</i> , 2020, 180, 208-208.e1.	13.5	58
122	Histiocytosis. <i>Lancet, The</i> , 2021, 398, 157-170.	6.3	58
123	Detection of an NRAS mutation in Erdheim-Chester disease. <i>Blood</i> , 2013, 122, 1089-1091.	0.6	57
124	ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. <i>Nature Communications</i> , 2017, 8, 15429.	5.8	55
125	Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway. <i>Nature Communications</i> , 2021, 12, 1826.	5.8	54
126	Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: possible role in <i>20q</i> polycythemia vera. <i>Blood</i> , 2010, 116, 2812-2821.	0.6	51

#	ARTICLE	IF	CITATIONS
127	Selective Activity of the Histone Deacetylase Inhibitor AR-42 against Leukemia Stem Cells: A Novel Potential Strategy in Acute Myelogenous Leukemia. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1979-1990.	1.9	49
128	Epigenetic alterations in hematopoietic malignancies. <i>International Journal of Hematology</i> , 2012, 96, 413-427.	0.7	48
129	The Role of Additional Sex Combs-Like Proteins in Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2016, 6, a026526.	2.9	48
130	Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. <i>Leukemia Research</i> , 2012, 36, 1500-1504.	0.4	47
131	Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. <i>Journal of Clinical Investigation</i> , 2018, 128, 3819-3825.	3.9	45
132	Genetics of the myeloproliferative neoplasms. <i>Current Opinion in Hematology</i> , 2011, 18, 117-123.	1.2	44
133	Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia. <i>Leukemia</i> , 2019, 33, 390-402.	3.3	44
134	Recurrent SRSF2 mutations in MDS affect both splicing and NMD. <i>Genes and Development</i> , 2020, 34, 413-427.	2.7	44
135	Sex-Biased <i>ZRSR2</i> Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis. <i>Cancer Discovery</i> , 2022, 12, 522-541.	7.7	44
136	Dissecting the Contributions of Cooperating Gene Mutations to Cancer Phenotypes and Drug Responses with Patient-Derived iPSCs. <i>Stem Cell Reports</i> , 2018, 10, 1610-1624.	2.3	43
137	Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms. <i>Blood</i> , 2020, 136, 1477-1486.	0.6	43
138	Aberrant Epigenetic and Genetic Marks Are Seen in Myelodysplastic Leukocytes and Reveal Dock4 as a Candidate Pathogenic Gene on Chromosome 7q. <i>Journal of Biological Chemistry</i> , 2011, 286, 25211-25223.	1.6	41
139	HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders. <i>Journal of Experimental Medicine</i> , 2013, 210, 339-353.	4.2	41
140	Clinical Implications of Novel Mutations in Epigenetic Modifiers in AML. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 1119-1133.	0.9	40
141	Single-agent dabrafenib for <i>BRAF</i> ^{V600E} -mutated histiocytosis. <i>Haematologica</i> , 2018, 103, e177-e180.	1.7	40
142	ZBTB1 Regulates Asparagine Synthesis and Leukemia Cell Response to L-Asparaginase. <i>Cell Metabolism</i> , 2020, 31, 852-861.e6.	7.2	40
143	Splicing factor mutations in hematologic malignancies. <i>Blood</i> , 2021, 138, 599-612.	0.6	40
144	Collaborating constitutive and somatic genetic events in myeloid malignancies: ASXL1 mutations in patients with germline GATA2 mutations. <i>Haematologica</i> , 2014, 99, 201-203.	1.7	39

#	ARTICLE	IF	CITATIONS
145	ASXL1 plays an important role in erythropoiesis. <i>Scientific Reports</i> , 2016, 6, 28789.	1.6	38
146	Cancer-Specific Splicing Changes and the Potential for Splicing-Derived Neoantigens. <i>Cancer Cell</i> , 2018, 34, 181-183.	7.7	38
147	Histiocytic neoplasms in the era of personalized genomic medicine. <i>Current Opinion in Hematology</i> , 2016, 23, 416-425.	1.2	37
148	Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML. <i>Cancer Discovery</i> , 2019, 9, 872-889.	7.7	36
149	Therapeutic Modulation of RNA Splicing in Malignant and Non-Malignant Disease. <i>Trends in Molecular Medicine</i> , 2021, 27, 643-659.	3.5	36
150	The Spliceosome as an Indicted Conspirator in Myeloid Malignancies. <i>Cancer Cell</i> , 2011, 20, 420-422.	7.7	35
151	Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by <i>MAP2K1</i> . <i>Haematologica</i> , 2020, 105, e5-e8.	1.7	34
152	Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome. <i>Blood</i> , 2022, 139, 2038-2049.	0.6	34
153	Histiocytosis and the nervous system: from diagnosis to targeted therapies. <i>Neuro-Oncology</i> , 2021, 23, 1433-1446.	0.6	33
154	Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series. <i>Neuro-Oncology</i> , 2020, 22, 979-992.	0.6	31
155	High frequency of clonal hematopoiesis in Erdheim-Chester disease. <i>Blood</i> , 2021, 137, 485-492.	0.6	30
156	Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis. <i>Leukemia Research</i> , 2013, 37, 32-36.	0.4	29
157	Somatic alterations and dysregulation of epigenetic modifiers in cancers. <i>Biochemical and Biophysical Research Communications</i> , 2014, 455, 24-34.	1.0	29
158	Role of TET2 and ASXL1 Mutations in the Pathogenesis of Myeloproliferative Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 1053-1064.	0.9	28
159	How do messenger RNA splicing alterations drive myelodysplasia?. <i>Blood</i> , 2017, 129, 2465-2470.	0.6	28
160	Molecular Pathways: Understanding and Targeting Mutant Spliceosomal Proteins. <i>Clinical Cancer Research</i> , 2017, 23, 336-341.	3.2	28
161	Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor. <i>Journal of Clinical Investigation</i> , 2020, 130, 6668-6676.	3.9	28
162	MSI2 is required for maintaining activated myelodysplastic syndrome stem cells. <i>Nature Communications</i> , 2016, 7, 10739.	5.8	27

#	ARTICLE	IF	CITATIONS
163	ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine. <i>Blood Cancer Journal</i> , 2021, 11, 157.	2.8	27
164	H3B-8800, an Orally Bioavailable Modulator of the SF3b Complex, Shows Efficacy in Spliceosome-Mutant Myeloid Malignancies. <i>Blood</i> , 2016, 128, 966-966.	0.6	27
165	Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia. <i>British Journal of Haematology</i> , 2016, 175, 402-409.	1.2	26
166	Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1149-1157.	1.9	26
167	Interpreting new molecular genetics in myelodysplastic syndromes. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 56-64.	0.9	26
168	ETV6-ABL1-positive "chronic myeloid leukemia": clinical and molecular response to tyrosine kinase inhibition. <i>Haematologica</i> , 2011, 96, 342-343.	1.7	24
169	Modeling SF3B1 Mutations in Cancer: Advances, Challenges, and Opportunities. <i>Cancer Cell</i> , 2016, 30, 371-373.	7.7	24
170	Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester disease. <i>Blood</i> , 2016, 128, 1896-1898.	0.6	24
171	Splicing factor SF3B1K700E mutant dysregulates erythroid differentiation via aberrant alternative splicing of transcription factor TAL1. <i>PLoS ONE</i> , 2017, 12, e0175523.	1.1	24
172	ProteomeGenerator: A Framework for Comprehensive Proteomics Based on de Novo Transcriptome Assembly and High-Accuracy Peptide Mass Spectral Matching. <i>Journal of Proteome Research</i> , 2018, 17, 3681-3692.	1.8	24
173	<i>Asxl1</i> loss cooperates with oncogenic <i>Nras</i> in mice to reprogram the immune microenvironment and drive leukemic transformation. <i>Blood</i> , 2022, 139, 1066-1079.	0.6	24
174	Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells. <i>Nature Biotechnology</i> , 2022, 40, 1103-1113.	9.4	24
175	Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. <i>Leukemia and Lymphoma</i> , 2014, 55, 1968-1979.	0.6	23
176	Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2010, 85, 81-83.	2.0	22
177	Mutant SF3B1 promotes AKT- and NF- κ B-driven mammary tumorigenesis. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	22
178	2-Hydroxyglutarate in <i>IDH</i> mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. <i>Leukemia and Lymphoma</i> , 2013, 54, 408-410.	0.6	21
179	U2af1 is required for survival and function of hematopoietic stem/progenitor cells. <i>Leukemia</i> , 2021, 35, 2382-2398.	3.3	21
180	The mutational landscape of paroxysmal nocturnal hemoglobinuria revealed: new insights into clonal dominance. <i>Journal of Clinical Investigation</i> , 2014, 124, 4227-4230.	3.9	20

#	ARTICLE	IF	CITATIONS
181	Identification and Targeting of Kinase Alterations in Histiocytic Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 705-719.	0.9	20
182	AXL Inhibition in Macrophages Stimulates Host-versus-Leukemia Immunity and Eradicates Na ⁺ ve and Treatment-Resistant Leukemia. <i>Cancer Discovery</i> , 2021, 11, 2924-2943.	7.7	20
183	Structural basis of cytokine-mediated activation of ALK family receptors. <i>Nature</i> , 2021, 600, 143-147.	13.7	20
184	Diffuse reduction of cerebral grey matter volumes in Erdheim-Chester disease. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 109.	1.2	19
185	Unlike <i>ASXL1</i> and <i>ASXL2</i> mutations, <i>ASXL3</i> mutations are rare events in acute myeloid leukemia with t(8;21). <i>Leukemia and Lymphoma</i> , 2016, 57, 199-200.	0.6	19
186	Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target. <i>Leukemia</i> , 2021, 35, 1037-1052.	3.3	19
187	Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic. <i>Genes and Development</i> , 2022, 36, 259-277.	2.7	19
188	Loss of <i>Asxl1</i> Alters Self-Renewal and Cell Fate of Bone Marrow Stromal Cells, Leading to Bohring-Opitz-like Syndrome in Mice. <i>Stem Cell Reports</i> , 2016, 6, 914-925.	2.3	18
189	<i>ABCA1</i> Exerts Tumor-Suppressor Function in Myeloproliferative Neoplasms. <i>Cell Reports</i> , 2020, 30, 3397-3410.e5.	2.9	18
190	Leveraging Systematic Functional Analysis to Benchmark an <i>In Silico</i> Framework Distinguishes Driver from Passenger MEK Mutants in Cancer. <i>Cancer Research</i> , 2020, 80, 4233-4243.	0.4	18
191	A Novel Germline Variant in <i>CSF3R</i> Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia. <i>Cancer Research</i> , 2018, 78, 6762-6770.	0.4	17
192	A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease. <i>Blood Advances</i> , 2019, 3, 934-938.	2.5	17
193	MAP-Kinase-Driven Hematopoietic Neoplasms: A Decade of Progress in the Molecular Age. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a034892.	2.9	17
194	Splicing factor mutations in MDS RARS and MDS/MPN-RS-T. <i>International Journal of Hematology</i> , 2017, 105, 720-731.	0.7	16
195	Novel activating <i>BRAF</i> fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26699.	0.8	16
196	Somatic gene mutations expose cytoplasmic DNA to co-opt the cGAS/STING/NLRP3 axis in myelodysplastic syndromes. <i>JCI Insight</i> , 2022, 7, .	2.3	16
197	Recent Discoveries in Molecular Characterization of Acute Myeloid Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 93-99.	1.2	15
198	The Effect of <i>SF3B1</i> Mutation on the DNA Damage Response and Nonsense-Mediated mRNA Decay in Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 609409.	1.3	15

#	ARTICLE	IF	CITATIONS
199	Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center. <i>British Journal of Haematology</i> , 2015, 171, 84-90.	1.2	14
200	Genetic basis for iMCD-TAFRO. <i>Oncogene</i> , 2020, 39, 3218-3225.	2.6	14
201	Interpreting new molecular genetics in myelodysplastic syndromes. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 56-64.	0.9	14
202	Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e566-e574.	2.2	13
203	Femoral Bone Marrow Aspiration in Live Mice. <i>Journal of Visualized Experiments</i> , 2014, .	0.2	12
204	Muscarinic acetylcholine receptor regulates self-renewal of early erythroid progenitors. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	12
205	Recent advances in the treatment of acute myeloid leukemia. <i>F1000 Medicine Reports</i> , 2010, 2, 55.	2.9	12
206	Focus on the epigenome in the myeloproliferative neoplasms. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 538-544.	0.9	11
207	The importance of subclonal genetic events in MDS. <i>Blood</i> , 2013, 122, 3550-3551.	0.6	11
208	Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations. <i>Blood</i> , 2020, 135, 1032-1043.	0.6	11
209	EZH2 Mutations: Mutating the Epigenetic Machinery in Myeloid Malignancies. <i>Cancer Cell</i> , 2010, 18, 105-107.	7.7	10
210	Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	10
211	Importance of Genetics in the Clinical Management of Chronic Myelomonocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2013, 31, 2374-2376.	0.8	9
212	Genetic drivers of vulnerability and resistance in relapsed acute lymphoblastic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 11071-11073.	3.3	9
213	Therapeutic targeting of RNA splicing in myelodysplasia. <i>Seminars in Hematology</i> , 2017, 54, 167-173.	1.8	9
214	ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1. <i>Molecular Cell</i> , 2022, 82, 2443-2457.e7.	4.5	9
215	First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl. <i>Blood</i> , 2019, 134, 3998-3998.	0.6	8
216	Molecular genetics of acute myeloid leukemia: clinical implications and opportunities for integrating genomics into clinical practice. <i>Hematology</i> , 2012, 17, s39-s42.	0.7	7

#	ARTICLE	IF	CITATIONS
217	Disordered Epigenetic Regulation in the Pathophysiology of Myeloproliferative Neoplasms. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 34-42.	1.2	7
218	Hairy cell leukemia. <i>Current Opinion in Hematology</i> , 2015, 22, 355-361.	1.2	7
219	Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". <i>Nature Medicine</i> , 2016, 22, 578-579.	15.2	7
220	Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim-Chester disease patients following BRAF inhibitor monotherapy. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa024.	0.4	7
221	Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms. <i>Haematologica</i> , 2014, 99, 797-801.	1.7	6
222	Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. <i>Leukemia and Lymphoma</i> , 2015, 56, 1938-1948.	0.6	6
223	PTEN isoforms with dual and opposing function. <i>Nature Cell Biology</i> , 2019, 21, 1306-1308.	4.6	6
224	Synthetic Lethal Interactions of MDS-Associated Spliceosomal Gene Mutations Identifies the Basis for Their Mutual Exclusivity. <i>Blood</i> , 2016, 128, 961-961.	0.6	6
225	Activating p53 and Inhibiting Superenhancers to Cure Leukemia. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 1002-1004.	4.0	5
226	Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study. <i>Blood</i> , 2016, 128, 480-480.	0.6	5
227	Modulation of RNA Splicing Enhances Response to BCL2 Inhibition in Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 507-507.	0.6	5
228	Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms. <i>Leukemia and Lymphoma</i> , 2016, 57, 1517-1526.	0.6	4
229	Editorial overview: Cancer genomics: RNA metabolism and translation in cancer pathogenesis and therapy. <i>Current Opinion in Genetics and Development</i> , 2018, 48, iv-vi.	1.5	4
230	Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900. <i>Haematologica</i> , 2019, 104, e147-e150.	1.7	4
231	High-Throughput Mutational Profiling In AML: Mutational Analysis of the ECOG E1900 Trial. <i>Blood</i> , 2010, 116, 851-851.	0.6	4
232	Splicing-Mediated Antigen Escape from Immunotherapy for B-cell Malignancies. <i>Blood Cancer Discovery</i> , 2021, , .	2.6	4
233	Targeting mRNA Decapping in AML. <i>Cancer Cell</i> , 2018, 33, 339-341.	7.7	3
234	Promoting spliceosome assembly for therapeutic intent. <i>Trends in Pharmacological Sciences</i> , 2021, 42, 981-983.	4.0	3

#	ARTICLE	IF	CITATIONS
235	<i>BRAF</i> -mutant hematopoietic malignancies. <i>Oncotarget</i> , 2014, 5, 7980-7981.	0.8	3
236	Single-Cell Multi-Omics Defines the Cell-Type Specific Impact of SF3B1 Splicing Factor Mutations on Hematopoietic Differentiation in Human Clonal Hematopoiesis and Myelodysplastic Syndromes. <i>Blood</i> , 2021, 138, 145-145.	0.6	3
237	Translocation t(11;17) in de novo Myelodysplastic Syndrome Not Associated with Acute Myeloid or Acute Promyelocytic Leukemia. <i>Acta Haematologica</i> , 2013, 129, 48-54.	0.7	2
238	Splicing regulation in hematopoiesis. <i>Current Opinion in Hematology</i> , 2021, 28, 277-283.	1.2	2
239	Dynamics of Mutant Alleles in Patients with Advanced Essential Thrombocythemia (ET) or Polycythemia (PV) During Pegylated Interferon-Alfa-2A (PEG-IFN- α -2A; Pegasys) Therapy. <i>Blood</i> , 2011, 118, 281-281.	0.6	2
240	Identification Of Actionable Genomic Alterations In Hematologic Malignancies By a Clinical Next Generation Sequencing-Based Assay. <i>Blood</i> , 2013, 122, 230-230.	0.6	2
241	Isogenic iPSC Models of SRSF2-Mutant Myelodysplastic Syndrome Capture Disease Phenotypes, Splicing Defects and Drug Responses. <i>Blood</i> , 2016, 128, 962-962.	0.6	2
242	Integrated Molecular Analysis Identifies Replicative Stress As Sensitizer to Imetelstat Therapy in AML. <i>Blood</i> , 2017, 130, 798-798.	0.6	2
243	Partial loss of genes might open therapeutic window. <i>ELife</i> , 2017, 6, .	2.8	2
244	First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl. <i>Blood</i> , 2021, 138, 43-43.	0.6	2
245	FISHing for TET2: Utility of FISH for TET2 deletions detection in clinical samples. <i>Leukemia Research</i> , 2012, 36, 25-26.	0.4	1
246	Refining the prognostic importance of the diversity of <i>FLT3</i> internal tandem duplications. <i>Leukemia and Lymphoma</i> , 2013, 54, 3-4.	0.6	1
247	Oncogenic splicing regulated by phase separation. <i>Nature Cell Biology</i> , 2020, 22, 916-918.	4.6	1
248	Spliceosomal Disruption of the Non-Canonical SWI/SNF Chromatin Remodeling Complex in SF3B1 Mutant Leukemias. <i>Blood</i> , 2019, 134, 637-637.	0.6	1
249	Male-Biased Spliceosome Mutations in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Impair pDC Activation and Apoptosis. <i>Blood</i> , 2020, 136, 13-14.	0.6	1
250	SRSF2-P95H delays Myelofibrosis Development through Altered JAK/STAT Signaling in JAK2-V617F Megakaryocytes. <i>Blood</i> , 2021, 138, 2544-2544.	0.6	1
251	Zanubrutinib, Obinutuzumab, and Venetoclax in Chronic Lymphocytic Leukemia: Early MRD Kinetics Define a High-Risk Patient Cohort with Delayed Bone Marrow Undetectable MRD and Earlier Post-Treatment MRD Recurrence. <i>Blood</i> , 2021, 138, 3753-3753.	0.6	1
252	High Throughput Single-Cell Simultaneous Genotyping and Chromatin Accessibility Reveals Genotype to Phenotype Relationship in Human Myeloproliferation. <i>Blood</i> , 2021, 138, 678-678.	0.6	1

#	ARTICLE	IF	CITATIONS
253	Venetoclax Therapy for Relapsed and Treatment Refractory AML: Clinical Outcomes and Molecular Predictors. <i>Blood</i> , 2020, 136, 47-48.	0.6	1
254	<i>ZRSR2</i> Mutation Induced Minor Intron Retention Drives MDS and Diverse Cancer Predisposition Via Aberrant Splicing of <i>LZTR1</i> . <i>Blood</i> , 2020, 136, 10-11.	0.6	1
255	Genetics of the Myeloproliferative Neoplasms. , 2011, , 39-68.		0
256	Modeling CBL activating mutations in vivo. <i>Blood</i> , 2017, 129, 2046-2048.	0.6	0
257	Stem Cell Model of Hematologic Diseases. , 2018, , 111-118.		0
258	BRAF in the cross-hairs. <i>Expert Review of Hematology</i> , 2019, 12, 183-193.	1.0	0
259	Hairy Cell Leukemia. , 2020, , 1872-1883.e5.		0
260	mRNA Export as a Novel Cancer-Specific Dependency. <i>Cancer Discovery</i> , 2021, 11, 2129-2131.	7.7	0
261	JAK2V617F-Mediated Phosphorylation of PRMT5 Down-Regulates Its Methyltransferase Activity and Promotes Myeloproliferation. <i>Blood</i> , 2010, 116, 794-794.	0.6	0
262	Conditional Deletion of <i>Asxl1</i> Results in Myelodysplasia. <i>Blood</i> , 2012, 120, 308-308.	0.6	0
263	Removal of Macrophages From the Erythroid Niche Impairs Stress Erythropoiesis but Improves Pathophysiology of Polycythemia Vera and Beta-Thalassemia. <i>Blood</i> , 2012, 120, 81-81.	0.6	0
264	Oncogenic Mutations in <i>XPO1</i> Promote Lymphoid Transformation By Altering Nuclear/Cytoplasmic Localization of NF κ B Signaling Intermediates. <i>Blood</i> , 2017, 130, 879-879.	0.6	0
265	Characterization of Ntrk fusions and Therapeutic Response to Ntrk Inhibition in Hematologic Malignancies. <i>Blood</i> , 2017, 130, 794-794.	0.6	0
266	Aberrant RNA Splicing Contributes to the Pathogenesis of EVI-Rearranged Myeloid Leukemias. <i>Blood</i> , 2019, 134, 917-917.	0.6	0
267	Impaired RAS Proteolysis Drives Clonal Hematopoietic Transformation. <i>Blood</i> , 2021, 138, 356-356.	0.6	0